Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. The audit was carried out between June 30-July 4, 2025 and has been concluded with No Critical and No Major observations.

Few other observations and recommendations were discussed during the inspection, which are procedural related.

Shilpa is committed to respond to the agency through appropriate CAPA plan on the other and recommendations points within the stipulated timelines.